

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Thursday, June 08, 2017 12:00 PM  
**To:** 'Rizwana Sproule'  
**Cc:** 'Nadia Agopyan'; 'Alex Babayan'  
**Subject:** BLA 125643 Clinical Risk Management (Yescarta investigator training materials) IR June 8, 2017

**Importance:** High

Dear Dr. Sproule,

We have the following request for the training materials Kite Pharma used to train investigators/HCPs in the clinical trials for Yescarta? Also, please detail any safety-related modifications you made in the materials, and the safety reasons/incidences for the modifications.

**Please respond by June 13, 2017.**

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax: 301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."